Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06856603

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites

Currently, the standard of care for patients with diagnosed metastatic cancer is drug therapy (chemotherapy, targeted therapy, or immunotherapy). However, the approach to oligometastatic disease (1-5 metastases) is evolving. An increasing number of de novo, persistent, and progressive oligometastatic tumors are now being treated with curative intent, with radiation therapy among the most effective treatment options, applied to metastatic sites in ablative doses. Emerging results from the SABR-COMET 3 and 5 trials, which investigate stereotactic ablative radiotherapy for patients with 1-3 and 1-5 metastatic sites, demonstrate a clear improvement in overall survival. However, patients with more than five metastases remain in a gray area.

The aim of our study is to assess the safety and effectiveness of radiation treatment for patients with tumors of various localizations and 6 to 10 metastases in the bones and internal organs. Stereotactic radiation therapy will be applied to patients with persistent or progressive metastatic forms of tumors, without changing their ongoing drug therapy regimen.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Metastatic Disease Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

A. Tsyb Medical Radiological Research Center

Obninsk, Kaluga Oblast, 249033, Russia

Location status: Recruiting

About this study

  • A patient with a previously verified diagnosis of a malignant neoplasm of any localization (ICD 10-11 codes C) who meets the inclusion criteria, after approval by the tumor board for the study group, will undergo the following procedures:

Three-dimensional/four-dimensional computed tomography for simulation using specialized fixation devices (the choice of the CT method and fixation devices will depend on the location of the metastasis).

The resulting images will be added to the contouring program.

Delineation of targets and organs at risk will be performed.

Clinical volumes and error margins will be determined.

  • The total dose per target and dose limits for critical structures will be prescribed.

Dosimetric planning for the course of external beam radiation therapy will be carried out.

Irradiation sessions will be conducted on a linear accelerator with a multi-leaf collimator, including a function for visual control of the target using cone beam tomography with kilo-voltage/mega-voltage radiation.

When the target is localized in the lungs, liver, or adrenal glands, to reduce the radiation load on surrounding healthy tissues and achieve necessary control over the position of the metastasis, irradiation will be performed with a deep breath hold or at specific phases of respiration.

  • Tumor Localization / Description / Total Focal Dose (Gy) / Number of Fractions / Single Focal Dose (Gy) / Irradiation Mode:

Lung Tumors:

Tumors ≤ 3 cm located in the parenchyma: TD 45 Gy in 3 fractions with 15 Gy each day Tumors adjacent to the chest wall or < 3 cm: TD 50 Gy in 5 fractions with 10 Gy each day Tumors within 2 cm of the mediastinum or brachial plexus: TD 60 Gy in 8 fractions with 7.5 Gy each day Bones: TD 24 Gy in 3 fractions with 8 Gy each day

Brain Metastases:

Tumor volume from 0.5 to 5 cm³: TD 20-22 Gy in 1 fraction at a time Tumor volume from 5 to 10 cm³: TD 16-18 Gy or TD 18-20 Gy in 1 fraction at a time Liver: Radiation regimen selection based on the tolerance of surrounding tissues and proximity to critical structures: TD 30-60 Gy in 3-8 fractions with 6-15 Gy each day

Adrenal Glands: TD 60 Gy in 8 fractions with 7.5 Gy each day

  • Expected Duration of Patient Participation in Clinical Testing:

Pre-hospital period: Comprehensive examination of the patient before treatment. Inpatient period: Includes pre-radiation preparation for up to 3 working days, SABR treatment for 1 to 8 working days.

Follow-up period: 3, 6, 9, and 12 months post-treatment; thereafter, follow-up will occur every 6 months up to 60 months.

Collection and processing of received data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ECOG status 0-3
  • Persistent or progressive cancer disease with 6 to 10 metastases
  • ≤ 5 metastases in one organ
  • Life expectancy > 6 months for intracranial lesions
  • Inability to surgically resect all metastatic lesions
  • Positive tumor board decision for trial inclusion
  • Signed informed consent

Exclusion criteria

  • ECOG status 4
  • De novo metastatic disease
  • Radiological complete response after drug therapy
  • Brain metastasis only
  • Brain metastasis > 3 cm, requiring neurosurgery
  • Size of any metastasis > 5 cm
  • Previous radiation therapy for any metastatic site
  • Leptomeningeal, pleural, or peritoneal carcinomatosis
  • Spinal cord compression, requiring neurosurgery
  • Invasion of great vessels, skin, or GI tract
  • Negative tumor board decision for trial inclusion
  • Unsigned informed consent

Treatment and study plan

stereotactic radiation therapy in ablative doses to each metastatic site

Radiation

Stereotactic ablative radiation therapy will be utilized for each metastatic site in patients with 6 to 10 sites of metastasis (persistent or progressive disease).

Primary outcomes

  1. Treatment safety

    Time frame: End of years 1, 2, 3, 4, 5 (study completion)

    Radiation-induced toxicity (type and corresponding grade 1 to 5) will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 scale.

Secondary outcomes

  1. Effectiveness (PFS)

    Time frame: From the date of initiation until the date of documented disease progression, assessed over a period of up to 60 months.

    Progression-free survival, assessed in months

  2. Effectiveness (LC)

    Time frame: From the date of initiation until the date of documented radiological signs of metastasis relapse, assessed over a period of up to 60 months.

    Local control for irradiated metastatic sites, assessed in months

  3. Effectiveness (OS)

    Time frame: From the date of initiation until the date of death from any cause, assessed over a period of up to 60 months.

    Overall survival, assessed in months

  4. Time-to-CTX-change

    Time frame: End of years 1, 2, 3, 4, 5 (study completion)

    Period of current drug line prolongation, assessed in months

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

National Medical Research Radiological Centre of the Ministry of Health of Russia

Other

Registry information

Official study title

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients (6-10 Metastases): A Prospective Phase II Single-Arm Trial

Acronym: OLIGO-10

Important dates

Study start
2025
Primary completion
2027
Study completion
2030
First posted
Mar 4, 2025
Registry last updated
Mar 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.